Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;5(4):1237-1239.
doi: 10.3892/ol.2013.1189. Epub 2013 Feb 12.

Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A case report

Deiter J Duff  1 , Shadi Haddadin, Carl Freter, Chris Papageorgiou
Affiliations

Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A case report

Deiter J Duff et al. Oncol Lett. 2013 Apr.

Abstract

We report a case of tumor lysis syndrome (TLS) in a patient with gallbladder carcinoma. TLS has not been reported in association with this type of tumor. TLS typically occurs in cases of highly proliferative hematological malignancies and small cell carcinoma. Two factors that may have contributed to TLS in this case include multifactorial mild acute renal failure shortly before the administration of chemotherapy and the aggressive morphology of the gallbladder carcinoma, which was a poorly differentiated sarcomatoid variant. This case raises concern for the development of TLS in certain types of patients with solid tumors.

Keywords: gallbladder carcinoma; gemcitabine; renal failure; solid tumors; tumor lysis syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Abdominal CT scan showed a heterogeneous gallbladder fossa mass invading the right hepatic lobe and enlarged periportal, pericaval, and periaortic lymph nodes.
Figure 2
Figure 2
Photomicrograph of tumor showing poorly differentiated adenocarcinoma with brisk mitoses and atypical tripolar mitosis (hematoxylin and eosin, magnification, ×200).
Figure 3
Figure 3
Graph of tumor lysis syndrome laboratory parameters.
See this image and copyright information in PMC

References

    1. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence based review. J Clin Oncol. 2008;26:2767–2778. - PubMed
    1. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors – a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51:187–192. - PubMed
    1. Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol. 2009;15:4464–4466. - PMC - PubMed
    1. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British J Haem. 2010;149:578–586. - PubMed
    1. Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36:164–176. - PubMed

LinkOut - more resources